Cytosorbents (NASDAQ:CTSO) Announces Quarterly Earnings Results

Cytosorbents (NASDAQ:CTSO) issued its earnings results on Monday. The medical research company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04, Zacks reports. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The company had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.00 on Tuesday. The company has a 50 day moving average of $1.07 and a two-hundred day moving average of $1.05. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CTSO shares. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday, February 25th. StockNews.com initiated coverage on Cytosorbents in a research note on Wednesday, March 26th. They set a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.